Proposed Rinvoq Copies Infringe 34 Patents, AbbVie Says in Suit

AbbVie Inc. sued Sandoz Group AG and four other generic-drug makers alleging their proposed copies of the blockbuster immunosuppressant Rinvoq infringe combinations of 34 patents.

AbbVie’s 248-page, 136-count complaint, filed Monday in the US District Court for the District of Delaware, targets units of Indian producers Hetero Drugs Ltd., Aurobindo Pharma Ltd., Intas Pharmaceuticals Ltd., and Sun Pharmaceuticals Industries Inc., as well as Swiss-based Sandoz Group AG. It follows the generic manufacturers’ asking the US Food and Drug Administration to approve their versions of the drug, according to the complaint.

US sales of Rinvoq totaled $1.8 billion in 2022—3.1% ...